Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Humanigen, Inc. - Common Stock (NQ: HGEN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Humanigen, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Humanigen Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference in January 2022
From Humanigen, Inc.
Via Business Wire
Humanigen, Inc. (NASDAQ:HGEN) Investor Notice: Investigation over Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 12/13/2021 -- Certain directors of Humanigen, Inc are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Exposures COVID-19 Product Safety
Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update
From Humanigen, Inc.
Via Business Wire
The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference
From Humanigen, Inc.
Via Business Wire
Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Release of Abstracts at ASH
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Participation and Presentation at Multiple Conferences in November
From Humanigen, Inc.
Via Business Wire
European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19
From Humanigen, Inc.
Via Business Wire
First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML)
From Humanigen, Inc.
Via Business Wire
European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19
From Humanigen, Inc.
Via Business Wire
Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM‘21
From Humanigen, Inc.
Via Business Wire
Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting Highlighting C-Reactive Protein as a Biomarker for Identifying Patients Most Likely to Benefit from treatment with Lenzilumab
From Humanigen, Inc.
Via Business Wire
Humanigen’s Budget Impact Model Demonstrates Lenzilumab’s Potential Positive Economic Value in Hospitalized COVID-19 Patients
From Humanigen, Inc.
Via Business Wire
Humanigen Signs Contract With Clinigen for Lenzilumab Managed Access Program in Europe
From Humanigen, Inc.
Via Business Wire
NASDAQ:HGEN Investor Notice: Investigation over Potential Securities Laws Violations by Humanigen, Inc.
San Diego, CA -- (SBWIRE) -- 10/07/2021 -- An investigation was announced over potential securities laws violations by Humanigen, Inc. in connection with certain financial statements. 
Via SBWire
Exposures COVID-19 Product Safety
Humanigen Announces Participation and Presentation at Multiple Conferences in October
From Humanigen, Inc.
Via Business Wire
Humanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UK’s MHRA
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021
From Humanigen, Inc.
Via Business Wire
Humanigen Announces the European Medicines Agency Has Appointed a Rapporteur and Co-rapporteur as Part of the Process Related to the Planned Submission of a Marketing Authorization Application (MAA) for Lenzilumab
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Participation and Presentation at Multiple Conferences in September
From Humanigen, Inc.
Via Business Wire
FDA has declined Humanigen’s Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients
From Humanigen, Inc.
Via Business Wire
Humanigen Reports Second Quarter 2021 Financial Results
From Humanigen, Inc.
Via Business Wire
Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients
From Humanigen, Inc.
Via Business Wire
NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19
From Humanigen, Inc.
Via Business Wire
Humanigen’s Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab
From Humanigen, Inc.
Via Business Wire
UK’s MHRA accepts Humanigen’s submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review
From Humanigen, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.